CardiaCare has developed a wearable therapy for atrial fibrillation. CardiaCare's technology utilizes noninvasive peripheral neuromodulation to mediate a cardiovascular anti-arrhythmic response that reduces atrial fibrillation burden. The technology employs a closed-loop approach, involving monitoring and therapy. The wearable wrist-band combines advanced ECG and PPG sensors with AI-based treatment algorithms to induce a neuromodulation stimulus. CardiaCare's neuromodulation of the median and ulnar nerves balances sympathetic (stellate) and parasympathetic (vagus) tone via the brachial plexus. This induces a cardiovascular anti-arrhythmic response, reduces premature atrial contractions, modulates heart rate and rhythm, and reduces atrial fibrillation triggers and burden. CardiaCare is based on multiple clinical observations with neuromodulation therapy in patients with atrial fibrillation. CardiaCare has completed a technical and clinical proof of concept and secured its intellectual property.

CardiaCare (זיו הלת'קר)

CardiaCare (זיו הלת'קר)